Treatment of GLP-1 for Diabetic Bariatric Patients
NCT04624672 on ClinicalTrials.gov · last registry update 2023-11-14
Stopped early, having planned 3 participants. The sponsor logged completion for 18 July 2022. Primary outcome, as filed: RATE OF PARTIAL REMISSION OF DIABETES. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- TERMINATED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Geisinger Clinic
- Sponsor type
- Other
- Enrollment
- 3
- Started
- 2021-08-25
- Primary completion
- 2022-07-18 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
RATE OF PARTIAL REMISSION OF DIABETES
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.